A new age: the real-world development pathway
Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
Articles/ Pharma Market Access/ Quintiles - Articles/ Views and analysis
Linda Banks
clinical trials, data, drug development, ema, market access, patients, Real World Evidence, regulation, RWE
0 Comment
Pharma must be prepared to work collaboratively to establish the best benefit-risk profiles and outcomes.
Cancer/ Clinical/ Quintiles - Articles/ Views and analysis
Andrew McConaghie
2016, breakthrough, cancer, clinical trial, ESMO, immuno-oncology, immunotherapy, Oncology, patients, quintilesIMS, treatment
0 Comment
QuintilesIMS’s Cristina Oliva talks to pharmaphorum about her personal highlights from this year’s congress.
Cancer/ Quintiles - Articles/ R&D/ Views and analysis
Adam Jeffery
breakthrough, cancer, clinical trial, development, ESMO, immuno-oncology, pipeline, quintilesIMS, treatment
0 Comment
Clinical/ Quintiles - Articles/ Views and analysis
Andrew McConaghie
cancer, immuno-oncology, immunotherapy, pharma, quintiles, webinar
0 Comment
In the last two years, the first PD-1 checkpoint inhibitor drugs to reach patients have launched a revolution in cancer care.
Clinical/ Oncology/ Partner Content/ Press releases/ Quintiles/ Quintiles - Articles
Adam Jeffery
cancer immunotherapy, clinical trials, ESMO, Immuno, immuno-oncology, Oncology, pharma, quintiles, webinar
0 Comment